“…An increasing number of studies in a range of neurological diseases have used this approach to identify disease-relevant, cell-specific gene expression changes (Boone et al, 2013, Chu et al, 2009, Kumar et al, 2013, Pietersen et al, 2009, Simpson et al, 2011, Baker et al, 2015. To date, only two studies have employed LCM in the investigation of human MS cases: one identifying gene expression changes in total extracts from NAWM, peri-lesional and lesional regions compared to control WM (Mycko et al, 2012) and the other identifying transcriptomic changes in the vascular compartment in MS (Cunnea et al, 2010); with neither study specifically assessing changes in the astrocyte transcriptome.…”